These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9776211)

  • 1. Bleeding and thrombosis in myeloproliferative disorders.
    Landolfi R
    Curr Opin Hematol; 1998 Sep; 5(5):327-31. PubMed ID: 9776211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies.
    Landolfi R; Di Gennaro L; Novarese L; Patrono C
    Semin Thromb Hemost; 2006 Apr; 32(3):251-9. PubMed ID: 16673279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of bleeding and thrombosis in myeloproliferative disorders.
    Landolfi R; Marchioli R; Patrono C
    Thromb Haemost; 1997 Jul; 78(1):617-21. PubMed ID: 9198226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention.
    Landolfi R; Cipriani MC; Novarese L
    Best Pract Res Clin Haematol; 2006; 19(3):617-33. PubMed ID: 16781491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspirin in essential thrombocythemia: status quo and quo vadis.
    Griesshammer M; Bangerter M; van Vliet HH; Michiels JJ
    Semin Thromb Hemost; 1997; 23(4):371-7. PubMed ID: 9263354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders.
    Wehmeier A; Südhoff T; Meierkord F
    Semin Thromb Hemost; 1997; 23(4):391-402. PubMed ID: 9263357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts.
    Michiels JJ
    Pathol Biol (Paris); 2003 Apr; 51(3):167-75. PubMed ID: 12781799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bleeding and thrombosis in the myeloproliferative disorders.
    Schafer AI
    Blood; 1984 Jul; 64(1):1-12. PubMed ID: 6375757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
    Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
    Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives.
    Landolfi R; Patrono C
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():83-6. PubMed ID: 8951777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia.
    Michiels JJ; van Genderen PJ; Lindemans J; van Vliet HH
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():47-56. PubMed ID: 8951772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythromelalgia in thrombocythemia of various myeloproliferative disorders.
    Michiels JJ; ten Kate FJ
    Am J Hematol; 1992 Feb; 39(2):131-6. PubMed ID: 1550104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients.
    Wehmeier A; Daum I; Jamin H; Schneider W
    Ann Hematol; 1991 Aug; 63(2):101-6. PubMed ID: 1912029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The myeloproliferative disorders. An historical appraisal and personal experiences.
    Michiels JJ
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():1-14. PubMed ID: 8951768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombocytosis and Thrombosis: Is There Really a Correlation?
    Galvez C; Stein BL
    Curr Hematol Malig Rep; 2020 Aug; 15(4):261-267. PubMed ID: 32399765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Occurrence of haemorrhagic and thrombotic events in myeloproliferative disorders: a retrospective study of 108 patients.
    Grossi A; Rosseti S; Vannucchi AM; Rafanelli D; Ferrini PR
    Clin Lab Haematol; 1988; 10(2):167-75. PubMed ID: 3416575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bleeding and thrombosis in chronic myeloproliferative disorders: relation of platelet disorders to clinical aspects of the disease.
    Wehmeier A; Scharf RE; Fricke S; Schneider W
    Haemostasis; 1989; 19(5):251-9. PubMed ID: 2777137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.
    Stein BL; Martin K
    Blood; 2019 Nov; 134(22):1902-1911. PubMed ID: 31778549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.